Caldwell Sutter Capital, Inc. Atai Life Sciences N.V. Transaction History
Caldwell Sutter Capital, Inc.
- $218 Billion
- Q2 2025
A detailed history of Caldwell Sutter Capital, Inc. transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Caldwell Sutter Capital, Inc. holds 500 shares of ATAI stock, worth $2,790. This represents 0.0% of its overall portfolio holdings.
Number of Shares
500
Previous 500
-0.0%
Holding current value
$2,790
Previous $680,000
61.03%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ATAI
# of Institutions
111Shares Held
31.3MCall Options Held
494KPut Options Held
315K-
Ubs Group Ag7.7MShares$43 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.43MShares$30.3 Million0.02% of portfolio
-
Morgan Stanley New York, NY3.49MShares$19.5 Million0.0% of portfolio
-
Pale Fire Capital Se Prague, 2N2.64MShares$14.7 Million0.59% of portfolio
-
Black Rock Inc. New York, NY1.31MShares$7.29 Million0.0% of portfolio
About ATAI Life Sciences N.V.
- Ticker ATAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 165,875,008
- Market Cap $926M
- Description
- Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...